Please select the option that best describes you:
Is there any data to use PIK3CA-directed agents in mutated metastatic triple-negative breast cancer?
Answer from: Medical Oncologist at Academic Institution
PIK3CA inhibitors are not currently approved for use in patients with triple-negative (ER, PR, and HER2-negative) breast cancer. There is preclinical and early clinical work that indicates promise in patients with ER/PR negative, HER2 negative, PIK3CA mutated breast. A quick search finds that there ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but ham...